Halia Therapeutics and Biolexis Therapeutics' Partnership Successfully Identifies Novel Clinical Candidate Targeting NLRP3-Driven Neuroinflammation
LEHI, Utah, July 31, 2024 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat i…
